Invitrogen

Myeloperoxidase Monoclonal Antibody (2C7)

Advanced Verification

This Antibody was verified by Relative expression to ensure that the antibody binds to the antigen stated.

2 Published Figures

1 Reference

View all (71) Myeloperoxidase antibodies

Datasheet

Protocols

Questions & Answers

Tech Support

Datasheet

Protocols

Questions & Answers

Tech Support

Product Image Gallery

Myeloperoxidase Antibody in Immunocytochemistry (ICC/IF) — Immunofluorescence analysis of MPO was performed using HL-60 and Jurkat cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 15 minutes, and blocked with 2% BSA for 1 hour at room temperature. HL-60 and Jurkat cells were labeled with Myeloperoxidase Monoclonal Antibody (2C7) (Product # MA1-80878) at 1:100 dilution in 0.1% BSA, incubated at 4 degree Celsius overnight and then labeled with Goat anti-Mouse IgG (H+L), Superclonal™ Recombinant Secondary Antibody, Alexa Fluor 488 conjugate (Product # A28175) at a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with ProLong™ Diamond Antifade Mountant with DAPI (Product # P36962). F-actin (Panel c: red) was stained with Rhodamine Phalloidin (Product # R415). Panel d represents the merged image of HL-60 showing membranous localization. Panel e represents the merged image of Jurkat cells showing no expression for MPO protein. Panel f represents control cells with no primary antibody to assess background. The images were captured at 60X magnification.

Myeloperoxidase Antibody in Immunohistochemistry (Paraffin) (IHC (P)) — Immunohistochemical staining of human bone marrow. Formalin fixed, paraffin processed tissue using a Myeloperoxidase monoclonal antibody (Product # MA1-80878)

Myeloperoxidase Antibody in Flow Cytometry (Flow) — Flow cytometric analysis of permeabilized human peripheral blood granulocytes using a Myeloperoxidase monoclonal antibody (Product # MA1-80878)

Myeloperoxidase Antibody — Antibody specificity was demonstrated by detection of differential basal expression of the target across cell lines tested owing to their inherent genetic constitution. Relative expression of MPO was observed in HL-60 cells with membranous localization, in comparison to Jurkat using Anti-Myeloperoxidase Monoclonal Antibody (2C7) (Product # MA1-80878) in Immunofluorescence. {RE}

Product Details

MA1-80878

Applications	Tested Dilution	Publications
Western Blot (WB)	Non-reducing conditions	-
Immunohistochemistry (Paraffin) (IHC (P))	1:500-1:1,000	-
Immunohistochemistry (Frozen) (IHC (F))	1:1,000-1:5,000	-
Immunocytochemistry (ICC/IF)	1:100	View 1 publication 1 publication
Flow Cytometry (Flow)	1/50 - 1/100	-
ELISA (ELISA)	Assay-dependent	-

Product Specifications
Species Reactivity	Human
Published species	Not Applicable
Host/Isotype	Mouse / IgG1
Class	Monoclonal
Type	Antibody
Clone	2C7
Immunogen	Human Myeloperoxidase. View immunogen
Conjugate	Unconjugated
Form	Liquid
Concentration	1 mg/mL
Purification	Protein A
Storage buffer	PBS, pH 7.4
Contains	0.09% sodium azide
Storage conditions	Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
RRID	AB_934783

Product Specific Information

This antibody does not react with rat.

Non-reducing conditions are recommended for Western blot applications. A suggested positive control for immunohistochemical applications is bone marrow.

Mouse anti Human myeloperoxidase antibody, clone 2C7 recognizes human myeloperoxidase (MPO).

Target Information

Myeloperoxidase (MPO) is a hemoprotein that is abundantly expressed in neutrophils and secreted during their activation. Native Myeloperoxidase is represented as a covalently bound tetrameric complex of two glycosylated alpha chains with a molecular weight range of 59 - 64 kDa, and two unglycosylated beta chains (MW ~14 kDa) with total MW ~150 kDa and a theoretical pI of 9.2. Traditionally, myeloperoxidase was considered as a main target of anti-neutrophil cytoplasm antibodies (ANCA), the serological markers for certain systemic vasculities such as periarteriitis nodosa, microscopic polyarteriitis and pulmonary eosinophilic granulomatosis (Churg-Strauss syndrome). Low to moderate anti-myeloperoxidase autoantibody levels are also reported in rheumatoid arthritis. Recently, it was shown that myeloperoxidase participates in the initiation and progression of cardiovascular disease. Myeloperoxidase possesses potent proinflammatory properties and may contribute directly to tissue injury. Now Myeloperoxidase is under consideration as one of the most promising cardiac markers. Myeloperoxidase is part of the host defense system of polymorphonuclear leukocytes and myeloperoxidase is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN (polymorphonuclear leukocytes), MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.